Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "New Strategies in Cancer Pharmacotherapy: Development of Hormonal Antineoplastic Drugs, Cytotoxic Drugs and Targeted Therapies"
Deadline for manuscript submissions: 30 November 2019.
Cancer is a group of diseases characterized by abnormal growth and proliferation of cells which, in most cases, forms a tumor. Primary tumor growth is often accompanied by angiogenesis, progression, and metastasis. Some cancers are hormone-independent, whilst others are responsive to hormones (principally, sexual hormones in breast, prostate, and ovary cancers). For both hormone-dependent and independent cancers, the effectiveness of cytotoxic drugs is limited, and their use is often accompanied by severe adverse effects, leading to the continuous search for “next-generation” compounds and/or delivery strategies. Over the past two decades, great effort has been made to develop new effective therapies. In the case of hormone-dependent cancers, hormone antagonists, inhibitors, and analogues are currently used. In addition, emerging knowledge about the molecular mechanisms involved in the generation and progression of tumors has led to the design of promising therapies against specific molecular targets. The combination of hormonal analogues, classic or new-generation cytotoxic drugs, and targeted therapies (small RNAs, monoclonal antibodies) with new forms of drug delivery will hopefully have future successful application in cancer treatment.
This Special Issue “New strategies in cancer pharmacotherapy: Development of hormonal antineoplastic drugs, cytotoxic drugs and targeted therapies” will include reviews and original research on advances in cancer treatment. Novel insights into the development and assay of new compounds either alone or in combination are of particular interest for this issue.
Dr. Carlos Martínez-Campa
Dr. Carolina Alonso-González
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer treatment
- hormone analogues
- targeted therapy
- cytotoxic drugs
- signaling pathways
- gene expresión
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: The amuvatinib derivative, compound 6, inhibits mitochondria and kills tumor cells under glucose starvation
Authors: Barak Rotblat, etc.
Title: Berberis vulgaris: a potential antidote against ifosfamide induced toxicities and synergist for its anticancer effect
Authors: Muhammad Usman Mirza, etc.
Title: Anti-vascular agents in anticancer therapy
Authors: Ryszard Smolarczyk, etc.